When analyzing subgroups, no significant differences in efficacy were observed with respect to age, disease characteristics, bone marrow blast percentage, dose fractionization, or previous treatment. A significant correlation was observed with peripheral blood blast counts. In 19 patients with peripheral blood counts < 200/microliter, 8 responded (i.e., achieved one category of complete recovery as defined in advance). The correlation remained even when the endpoint was relaxed to included additional patients who had > 50% reduction in bone marrow blasts.
Presented By: Mark Berger from Actinium Pharmaceuticals, Inc.
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.